AI is increasingly competing with traditional SaaS businesses for both customers and investors, says Saagar Bhavsar, partner at Begin Capital. For one thing, artificial intelligence has businesses wondering if it’s more viable to build software tools in-house with the aid of new coding assistants and other AI agents.But Michael Carmen, co-head of private investments at Wellington Management and the coauthor of a venture capital outlook report the firm released in December, says AI companies have recently be ...

Core Viewpoint - MEDIROM Healthcare Technologies Inc. is collaborating with Tools for Humanity and World Foundation to implement Proof of Human technologies, such as World ID, across Japan, aiming to enhance trust in digital interactions and create new revenue streams [2][3][4]. Group 1: Collaboration and Agreements - MEDIROM has signed a Master Service Agreement (MSA) with Tools for Humanity and World Foundation to manage Proof of Human verification locations in Japan, which is expected to generate revenue through operational fees and related services [3]. - A dedicated task force, the "MEDIROM World Proof of Human Task Force," will be established to facilitate the nationwide rollout of Proof of Human technology [3][5]. Group 2: Background and Purpose - The collaboration addresses the challenge of distinguishing between humans and AI online, leveraging blockchain technology to provide a secure method for individuals to prove their humanity without disclosing their identity [4]. - The initiative aims to foster a digital society where everyone can participate confidently, enhancing the social implementation of Proof of Human [5]. Group 3: Key Initiatives - MEDIROM will deploy advanced cameras, known as Orbs, in approximately 300 Re.Ra.Ku Group locations to verify humanness while preserving privacy [6]. - Plans include establishing flagship locations and pop-up stores to enhance accessibility to Proof of Human verification services [11]. Group 4: Leadership Comments - Koji Eguchi, President and CEO of MEDIROM, expressed enthusiasm for the collaboration, emphasizing the importance of establishing a social infrastructure for proving humanness in the age of generative AI [7]. - Tomoe Makino, General Manager of Tools for Humanity Japan, highlighted Japan's leadership in adopting technology and the potential of Proof of Human as essential digital infrastructure [12].

Core Viewpoint - MEDIROM Healthcare Technologies Inc. is collaborating with Tools for Humanity and World Foundation to implement Proof of Human technologies, including World ID, across Japan, aiming to enhance trust in digital interactions and create new revenue streams for the company [2][3][4]. Group 1: Collaboration Details - MEDIROM has signed a Master Service Agreement with Tools for Humanity and World Foundation to manage Proof of Human verification locations in Japan, leveraging its network of approximately 300 physical locations [3][5]. - A dedicated task force, the "MEDIROM World Proof of Human Task Force," will be established to facilitate the nationwide rollout of this technology [3][5]. Group 2: Background and Purpose - The collaboration addresses the challenge of distinguishing between humans and AI online, which has become increasingly difficult due to advancements in generative AI [4]. - The World project aims to provide a blockchain-based mechanism for individuals to prove their humanity without revealing their identity, thereby fostering trust in digital environments [4][5]. Group 3: Key Initiatives - MEDIROM plans to expand its reach by establishing flagship locations and pop-up stores for Proof of Human verification services, enhancing accessibility for users [7][9]. - The company will utilize advanced camera technology, known as Orbs, to verify humanness at approximately 300 Re.Ra.Ku Group locations [9]. Group 4: Leadership Comments - Koji Eguchi, President and CEO of MEDIROM, expressed excitement about the collaboration, emphasizing the importance of establishing a social infrastructure for proving one's humanity in the digital age [6]. - Tomoe Makino, General Manager of Tools for Humanity Japan, highlighted Japan's leadership in adopting technology and the potential of Proof of Human as essential digital infrastructure [11].

Core Viewpoint - The comparison between MSP Recovery and Tivic Health Systems highlights the strengths and weaknesses of both small-cap medical companies, focusing on profitability, valuation, risk, analyst recommendations, institutional ownership, earnings, and dividends. Analyst Recommendations - Both MSP Recovery and Tivic Health Systems have a rating score of 1.00, with one sell rating each and no buy or strong buy ratings [2]. Earnings and Valuation - MSP Recovery reported gross revenue of $18.25 million, a price-to-sales ratio of 0.22, and a net income of -$360.50 million, resulting in an earnings per share of -$572.83 [4]. - Tivic Health Systems had gross revenue of $780,000, a price-to-sales ratio of 4.74, and a net income of -$5.66 million, leading to an earnings per share of -$6.68 [4]. - Despite lower revenue, Tivic Health Systems has higher earnings compared to MSP Recovery and is trading at a lower price-to-earnings ratio, indicating it is currently more affordable [4]. Institutional and Insider Ownership - Institutional ownership for MSP Recovery stands at 3.8%, while Tivic Health Systems has 4.3% [5]. - Insider ownership is significantly higher for MSP Recovery at 50.5%, compared to just 0.5% for Tivic Health Systems [5]. Volatility and Risk - MSP Recovery has a beta of -2.96, indicating its stock price is 396% less volatile than the S&P 500 [6]. - In contrast, Tivic Health Systems has a beta of 1.97, suggesting its stock price is 97% more volatile than the S&P 500 [6]. Profitability - MSP Recovery's net margins are at -7,328.48%, with a return on equity of -326.80% and a return on assets of -81.27% [8]. - Tivic Health Systems shows net margins of -1,557.26%, a return on equity of -202.20%, and a return on assets of -173.34% [8]. Summary - Tivic Health Systems outperforms MSP Recovery in 7 out of 11 factors compared between the two stocks [9].

Core Insights - Visory Health has announced a collaboration with Albertsons Companies to enhance access to affordable healthcare for veterans, families, and caregivers through its prescription discount card [1][2] - The partnership aims to address the rising costs of healthcare and medication, with over 9 million Americans reportedly skipping medication doses to save costs [2][3] - Customers can save up to 80% on medications by using the Visory Health discount card at participating Albertsons pharmacies [3] Company Overview - Visory Health is a health tech platform focused on providing affordable healthcare access, particularly for underserved populations, including veterans and families [5] - The company operates a network of over 37,000 pharmacy partners nationwide, including major retailers like Walgreens and Kroger, and offers a free-to-use model for customers [5] Partnership Details - The collaboration with Albertsons expands Visory Health's network of retail and pharmacy partners, which already includes Kroger and Food Lion [1] - Albertsons pharmacies provide various services, including vaccinations and health screenings, enhancing the convenience for customers using the Visory Health discount card [3] Accessibility Features - Customers can access their digital discount card through the Visory Health app available on the App Store and Google Play Store, or download it from the Visory Health website [4]

图片来源： Harvey 汤姆 ·凯利博士是一名创伤外科医生，他目睹各地医生深陷行政工作的泥潭。为了改变现状，他决定自己动手构建解决方案。 "我们希望打造一个能与临床医生并肩工作的 AI 护理助手，接管行政事务，让我们这样的医疗从业者能专注于毕生追求的诊疗工作，"他向 TechCrunch 表示。 凯利医生与曾在初创公司共事的瓦利德 ·穆萨联手，于 2021 年创立 Heidi Health 。该公司于 2024 年初开始推出产品。 他表示，仅用 18 个月时间，公司已为 116 个国家 / 地区的 7000 万次患者就诊释放了超过 "1800 万小时 " 的一线医疗资源。 Heidi 表示，其产品每周服务超过 200 万名临床医生，服务范围从大型医院到个体诊所不等。该产品提供基础免费版本和付费功能， Kelly 博士认 为这种模式能有效吸引新客户。 他表示，人工智能无疑将彻底改变医疗健康领域，但医疗服务的核心仍离不开人文关怀，特别是在建立和维系信任方面。 " 我们的目标是让全球医疗容量翻倍，这才是 AI 技术的真正潜力所在， " 他说道， " 我们正致力于实现这一愿景。 " 该产品正如承诺所言，是一款能处理 ...

Core Viewpoint - Enthusiasm for Michael Saylor's strategy and its imitators is waning, leading to significant stock declines for several companies in the past month [1] Group 1: Company Performance - Strategy's stock has decreased approximately 4% over the past month, underperforming bitcoin, which has increased by 3% [2] - Despite recent underperformance, Strategy's stock has surged by 2,800% since it began investing in bitcoin in 2020 [2] - Metaplanet (MTPLF), a Japanese hotel management firm turned bitcoin holding company, experienced a share price drop of over 36% in the last month [3] - Kindly MD (NAKA), a healthcare data provider, saw its shares decline by 87%, while Semler Scientific (SMLR) fell nearly 12% [3] - Trump Media & Technology Group (DJT), which launched a bitcoin treasury, has seen its shares fall by 8% [4] - A vehicle created by Cantor Fitzgerald (CEP) has dropped 17% as it prepares to take public a bitcoin treasury company [4] Group 2: Market Dynamics - The influx of companies attempting to replicate Strategy's model raises concerns about the sustainability of the bitcoin treasury stock boom [5] - Analyst Gus Galá noted that an oversaturation of similar strategies could lead to diminished investor demand [5] - Factors such as a surge in crypto prices, changes in US accounting rules, and a favorable regulatory environment under the Trump administration have fueled interest in companies imitating Strategy's approach [6] - Kevin O'Leary highlighted that many investors prefer holding equities over direct bitcoin investments, despite the availability of bitcoin exchange-traded funds [7]

Core Viewpoint - Verily, a health tech subsidiary of Alphabet, is facing serious allegations regarding unauthorized use of health data from over 25,000 patients and attempts to cover up these violations, as claimed by a former executive, Ryan Sloan [1][5][12]. Company Allegations - Ryan Sloan alleges that Verily improperly used patients' protected health information in various contexts, including research and marketing, affecting more than 25,000 patients in its diabetes program [5][6]. - An internal investigation confirmed multiple breaches of HIPAA Business Associate Agreements with large clients between 2017 and 2021 [6]. Legal Proceedings - Sloan's lawsuit, filed in federal court in San Francisco, has not been previously reported and is currently ongoing, with a judge denying Verily's request to dismiss the case [2][3]. - Verily has publicly stated that the allegations are without merit and that it will defend itself fully [3]. Company Operations and Structure - Verily, which began as a project in 2015 within Alphabet's innovation lab, has raised over $1 billion from investors but has struggled to find a successful product [13]. - The company is reportedly transitioning from an LLC to a C-corp structure to prepare for new funding [13]. Response to Allegations - Verily allegedly delayed notifying affected parties about the breaches and concealed the information during contract negotiations with clients [9][10]. - The company suppressed a press release that could have drawn attention to the violations, instructing employees not to mention it again [12]. Executive Actions - Sloan and another executive raised concerns about the breaches to senior management, but were reportedly dismissed, leading to Sloan's termination while on leave [12][11].

Summary of Certara FY Conference Call - September 10, 2025 Company Overview - **Company**: Certara (NasdaqGS:CERT) - **Industry**: Health Technology and Biosimulation Key Points and Arguments Growth Strategy - Certara is focused on accelerating organic growth despite a subdued market environment, targeting mid-single-digit growth rates [4][5] - Investments in sales, marketing, and R&D are being made to enhance the commercial organization and software platforms [4][5] - New software enhancements, including Certara IQ (AI-enabled software for Quantitative Systems Pharmacology, QSP), are expected to drive growth [5][10] R&D and Product Development - Certara is addressing critical pain points in drug development, particularly the high failure rates of drug trials, by enhancing software capabilities [7] - The company has launched Certara Cloud, which has seen rapid adoption, particularly among large biopharma customers [11][12] - The tiered customer structure includes: - **Tier 1**: Large biopharma (50% of revenue) - **Tier 2**: Mid-sized companies (20% of revenue) - **Tier 3**: Biotechs (30% of revenue) [14][15] Market Dynamics - The funding environment for tier three customers remains challenging, but Certara has successfully targeted biotechs with funding potential [13][15] - The FDA's directive to shift away from animal testing is seen as a tailwind for Certara, enhancing customer discussions and driving demand for SIMCYP and QSP [24][34] Financial Performance - Certara expects an adjusted EBITDA margin of 30-32% for the year, consistent with previous performance [20] - The company is on track to meet its full-year plan despite some timing issues in software bookings for tier one customers [16][17] AI and Technology Integration - The acquisition of Vyasa has enabled Certara to integrate AI technology into its workflow and product offerings [25][26] - The co-author tool for regulatory writing has demonstrated a 40% efficiency improvement, appealing to regulatory customers [27] M&A and Strategic Review - Certara is actively engaged in a strategic review of its regulatory business, which has returned to growth with a 20-30% adjusted EBITDA margin [43][44] - The company is focused on software acquisitions to shift its revenue mix from services to software, aiming for a balanced profitability profile [45][46] Capital Allocation - Certara prioritizes R&D investments while also considering M&A opportunities and share buybacks, having authorized a $100 million share repurchase program [47][48] Additional Important Insights - Certara's longstanding relationship with the FDA provides a competitive advantage, as many FDA users are familiar with Certara's software [32][33] - The company is well-positioned to help biopharma clients find efficiencies across the drug development cycle, from discovery to submission [30][31] - The integration of Camaxon, a chem-informatics software company, is progressing well, with expectations to enhance margins and product offerings [40][41]

Core Insights - The healthcare sector has underperformed in the S&P 500, with gains of about 10% in 2025 compared to a flat performance in healthcare [1] - Healthcare stocks are currently trading at a 10% discount to their fair value, marking one of the cheapest valuations in over five years [1][3] - Health tech is highlighted as a promising segment within healthcare, showing strong fundamentals and potential for capital growth [2][6] Healthcare Sector Performance - The healthcare sector is characterized by volatility and complexity, with both opportunities and risks tied to innovation [1] - The Health Care Select Sector SPDR Fund (XLV) has only increased by 3% since April, indicating underperformance relative to the broader market [2] Health Tech Segment - Health tech companies are capital and R&D intensive, focusing on disrupting traditional healthcare practices [2] - The ROBO Global Healthcare Technology and Innovation ETF (HTEC) has gained nearly 25% since April, outperforming the broader healthcare sector [2] - HTEC is currently trading at the bottom of its historic EV/sales ratio, suggesting a potential for correction and growth [3] Innovation and M&A Activity - Accelerating innovation in areas like genomics and robotics is driving growth in health tech [3][4] - AI-driven drug discovery is expected to significantly impact the sector, with an estimated $236 billion in revenues at risk due to expiring patents by 2030 [4] Valuation and Market Conditions - The healthcare sector is viewed as undervalued, presenting opportunities for investors seeking capital growth [6] - Macroeconomic pressures such as high-interest rates and inflation are easing, while demand for healthcare remains strong [6]